A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.

Zhou, Meng; Wang, Xiaoyu; Xia, Jie; Cheng, Yating; Xiao, Lichun; Bei, Yu; Tang, Jianzhong; Huang, Yadong; Xiang, Qi; Huang, Shiliang

Zhou, Meng; Wang, Xiaoyu; Xia, Jie; Cheng, Yating; Xiao, Lichun; Bei, Yu; Tang, Jianzhong; Huang, Yadong; Xiang, Qi; Huang, Shiliang.

Afiliação

Zhou M; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Wang X; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Xia J; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, People's Republic of China.
Cheng Y; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Xiao L; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Bei Y; Biopharmaceutical R&D Center of Jinan University, Guangzhou 510630, People's Republic of China.
Tang J; Biopharmaceutical R&D Center of Jinan University, Guangzhou 510630, People's Republic of China.
Huang Y; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Xiang Q; Biopharmaceutical R&D Center of Jinan University, Guangzhou 510630, People's Republic of China.
Huang S; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People's Republic of China.

Int J Nanomedicine ; 15: 3087-3098, 2020.

Article em En | MEDLINE | ID: mdl-32431503

Assuntos

Membro C3 da Família 1 de alfa-Ceto Redutase/antagonistas & inibidores; Antineoplásicos/química; Antineoplásicos/farmacologia; Terapia de Alvo Molecular/métodos; Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico; Animais; Anticorpos Monoclonais/química; Antineoplásicos/administração & dosagem; Linhagem Celular Tumoral; Quitosana/química; Sistemas de Liberação de Medicamentos/métodos; Humanos; Masculino; Camundongos Endogâmicos BALB C; Nanoestruturas/administração & dosagem; Nanoestruturas/química; Naftoquinonas/química; Antígeno Prostático Específico/metabolismo; Neoplasias de Próstata Resistentes à Castração/metabolismo; Neoplasias de Próstata Resistentes à Castração/patologia; Receptor ErbB-2/imunologia; Receptores Androgênicos/metabolismo; Sesquiterpenos/química; Testosterona/metabolismo; Ensaios Antitumorais Modelo de Xenoenxerto

Palavras-chave

castration-resistant prostate cancer; conjugate of HER2 monoclonal antibody extracellular fragment 4D5; mansonone derivative

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia de Alvo Molecular / Neoplasias de Próstata Resistentes à Castração / Membro C3 da Família 1 de alfa-Ceto Redutase / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google